SCHEMBL3522237

SCHEMBL3522237

COC(=O)CCCC#Cc1cc(Cl)ccc1NS(=O)(=O)c1ccc2c(c1)CCO2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 4/20 0.49
MAPT P10636 1/20 0.49
HDAC3 O15379 2/20 0.42
HDAC4 P56524 2/20 0.42
HDAC1 Q13547 2/20 0.42
HDAC7 Q8WUI4 2/20 0.42
HDAC2 Q92769 2/20 0.42
HDAC10 Q969S8 2/20 0.42
HDAC11 Q96DB2 2/20 0.42
HDAC8 Q9BY41 2/20 0.42
HDAC6 Q9UBN7 2/20 0.42
HDAC9 Q9UKV0 2/20 0.42
HDAC5 Q9UQL6 2/20 0.42
PKLR P30613 1/20 0.41
KDM4E B2RXH2 2/20 0.40
TSHR P16473 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALDH1A1 P00352 2/20 0.38
HPGD P15428 1/20 0.38
IDH1 O75874 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3521610 0.95 PKM (0.51) PKMMAPTHDAC3HDAC4HDAC1
SCHEMBL3522927 0.91 KDM4E (0.50) PKMMAPTKDM4ETSHRSMN1; SMN2
SCHEMBL3525917 0.88 HDAC3 (0.41) PKMMAPTHDAC3HDAC4HDAC1
SCHEMBL3523802 0.87 LMNA (0.47) MAPTHDAC3HDAC4HDAC1HDAC7
SCHEMBL3525207 0.87 PKM (0.45) PKMALDH1A1HPGDCCR2CCR9
SCHEMBL3528604 0.84 PTGES2 (0.47) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3526988 0.83 HDAC3 (0.42) PKMMAPTHDAC3HDAC4HDAC1
SCHEMBL3529380 0.82 PKM (0.48) PKMMAPTHDAC3HDAC4HDAC1
SCHEMBL3527524 0.82 PKM (0.51) PKMPKLRSMN1; SMN2ALDH1A1LMNA
SCHEMBL3526458 0.82 LMNA (0.48) PKMMAPTHDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP PKM 728/4885MAPT 214/4885HDAC3 1790/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG PKM 747/4885MAPT 730/4885HDAC3 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.